Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 11/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | CLK2 | P49760 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
| ▸ | PAK4 | O96013 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22368670 | 0.80 | PDK2 (0.47) | JAK2IGF1RJAK3KDM4E | |
| SCHEMBL24566893 | 0.80 | CHEK1 (0.35) | CHEK1CDK2 | |
| SCHEMBL17514151 | 0.75 | HCAR3 (0.41) | CDK2KDM4EALDH1A1 | |
| SCHEMBL1593008 | 0.74 | HPGDS (0.35) | JAK2JAK3CSF1RPIM1GSK3A | |
| SCHEMBL1592956 | 0.74 | GRM4 (0.32) | JAK2JAK3 | |
| SCHEMBL1592885 | 0.74 | IDO1 (0.38) | DYRK1BDYRK1AIGF1RALDH1A1LMNA | |
| SCHEMBL1585071 | 0.73 | DYRK1A (0.55) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL1592867 | 0.72 | DYRK1B (0.44) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL1585882 | 0.72 | DYRK1B (0.44) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL16537147 | 0.72 | DYRK1B (0.44) | DYRK1BDYRK1AAURKAJAK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| CN-112724134-B | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2022-04-01 | — | — | CN | disclosed |
| EP-3430005-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-112724134-A | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-04-30 | — | — | CN | disclosed |
| EP-3430005-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | Plexxikon Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2017161045-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267660-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKAR2B, AKT3, MAP3K11 | DYRK1B 362/4885DYRK1A 400/4885AURKA 389/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | DYRK1B 2843/4885DYRK1A 2883/4885AURKA 3774/4885 |
| US-10160747-B2 | Compounds and methods for kinase modulation, and indications therefor | PRKAR2B, AKT3, MAP3K11 | DYRK1B 362/4885DYRK1A 400/4885AURKA 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.